Alberta Investment Management Corp Has $4.90 Million Holdings in Zoetis Inc. (NYSE:ZTS)

Alberta Investment Management Corp increased its position in shares of Zoetis Inc. (NYSE:ZTS) by 2,050.0% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 30,100 shares of the company’s stock after acquiring an additional 28,700 shares during the quarter. Alberta Investment Management Corp’s holdings in Zoetis were worth $4,904,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in ZTS. Atlantic Edge Private Wealth Management LLC raised its holdings in shares of Zoetis by 482.8% during the fourth quarter. Atlantic Edge Private Wealth Management LLC now owns 169 shares of the company’s stock valued at $28,000 after acquiring an additional 140 shares during the period. Darwin Wealth Management LLC acquired a new stake in shares of Zoetis during the third quarter valued at approximately $31,000. First Personal Financial Services acquired a new stake in shares of Zoetis during the third quarter valued at approximately $33,000. Capital Performance Advisors LLP acquired a new stake in shares of Zoetis during the third quarter valued at approximately $33,000. Finally, Dunhill Financial LLC raised its holdings in shares of Zoetis by 80.6% during the third quarter. Dunhill Financial LLC now owns 168 shares of the company’s stock valued at $33,000 after acquiring an additional 75 shares during the period. Institutional investors and hedge funds own 92.80% of the company’s stock.

Zoetis Stock Performance

ZTS stock opened at $156.92 on Thursday. The company has a quick ratio of 1.08, a current ratio of 1.75 and a debt-to-equity ratio of 1.09. The company has a market capitalization of $70.27 billion, a price-to-earnings ratio of 28.69, a P/E/G ratio of 2.71 and a beta of 0.90. Zoetis Inc. has a 12 month low of $144.80 and a 12 month high of $200.53. The firm has a 50 day moving average of $167.29 and a two-hundred day moving average of $178.29.

Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Thursday, February 13th. The company reported $1.40 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.37 by $0.03. The business had revenue of $2.32 billion during the quarter, compared to the consensus estimate of $2.30 billion. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. As a group, equities analysts anticipate that Zoetis Inc. will post 6.06 EPS for the current fiscal year.

Zoetis Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 3rd. Investors of record on Monday, April 21st will be issued a dividend of $0.50 per share. This represents a $2.00 annualized dividend and a dividend yield of 1.27%. The ex-dividend date of this dividend is Monday, April 21st. Zoetis’s dividend payout ratio is currently 36.56%.

Insider Buying and Selling

In related news, EVP Roxanne Lagano sold 326 shares of the company’s stock in a transaction on Tuesday, February 11th. The shares were sold at an average price of $171.18, for a total transaction of $55,804.68. Following the completion of the sale, the executive vice president now directly owns 16,107 shares of the company’s stock, valued at approximately $2,757,196.26. This represents a 1.98 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.16% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

ZTS has been the topic of a number of research analyst reports. Morgan Stanley lowered their price objective on shares of Zoetis from $243.00 to $238.00 and set an “overweight” rating on the stock in a research report on Friday, February 14th. Leerink Partnrs raised shares of Zoetis to a “strong-buy” rating in a research report on Monday, December 2nd. Stifel Nicolaus lowered their price objective on shares of Zoetis from $210.00 to $180.00 and set a “buy” rating on the stock in a research report on Tuesday, January 7th. UBS Group initiated coverage on shares of Zoetis in a research report on Monday, December 9th. They set a “neutral” rating and a $196.00 price objective on the stock. Finally, Barclays boosted their price objective on shares of Zoetis from $242.00 to $244.00 and gave the company an “overweight” rating in a research report on Friday, February 14th. One investment analyst has rated the stock with a hold rating, ten have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, Zoetis presently has an average rating of “Buy” and a consensus target price of $214.90.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.